DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
Feng Xu, Lulu He, Xueqin Zhan, Jiexin Chen, Huan Xu, Xiaoling Huang, Yangyi Li, Xiaohe Zheng, Ling Lin, Yongsong Chen
Abstract
genes. Low-risk patients responded well to immunotherapy due to higher expression of immune checkpoint molecules and lower stemness index. Thus, our model predicted a favorable prognosis and increased overall survival for patients in the low-risk methylation group. Further, this model could provide potential drug targets to develop effective immunotherapies for LUAD.
Topics & Concepts
DNA methylationOncologyAdenocarcinomaMethylationMedicineInternal medicineCancer researchBiologyDNAGeneticsCancerGeneGene expressionCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisEpigenetics and DNA Methylation